论文信息 - A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. - 字舞流文

A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.

T. Stockley | E. Chen | D. Graham | P. Bradbury | U. Zurawska | M. Trinkaus | J. Rothenstein | J. H. Law | A. Fung | S. Gill | H. Albaba | S. Effendi | N. Leighl | D. Zawisza | L. Le | M. Chan | S. Arif | M. Sawczak | T. Zhang | K. Pisters